Input the laboratory and clinical parameters to visualize the CDI severity stratification.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Immediate bedside assessment of CDI severity to select initial therapy
Applying the 2021 IDSA/SHEA preference for Fidaxomicin over Vancomycin
To trigger surgical and critical care consultation in fulminant cases
Patient Population
Adults with acute clinical symptoms of C. difficile infection (≥ 3 loose stools/day) and a positive toxin or PCR assay.
Section 2
Formula & Logic
Thresholds for Severity
Non-Severe
WBC ≤ 15,000 AND Cr < 1.5 mg/dL
Severe
WBC > 15,000 OR Cr ≥ 1.5 mg/dL
Fulminant
Hypotension, Shock, Ileus, or Megacolon
2021 Drug Selection
01
Standard Case: Fidaxomicin (200 mg BID x 10 days) — First line preferred for all non-fulminant cases.
02
Alternative: Vancomycin (125 mg QID x 10 days) — Acceptable alternative if fidaxomicin is unavailable.
03
Metronidazole: No longer recommended as first-line for adults.
Section 3
Pearls/Pitfalls
Why Fidaxomicin?
The 2021 update shifted Fidaxomicin to the top-tier recommendation because it is associated with a significantly lower risk of "Global Cure" (initial cure plus no recurrence) compared to Vancomycin. Its narrow spectrum spares more of the protective gut microbiome.
The "Creatinine" Nuance
The creatinine threshold (≥ 1.5 mg/dL) refers to an increase from the patient's personal baseline. In chronic kidney disease patients, use clinical judgement regarding what constitutes an acute rise.
Clinical Pearls
Avoid anti-peristaltic agents (Loperamide) in patients with severe or fulminant CDI
Bezlotoxumab should be considered during the initial antibiotic course for patients at high risk of recurrence
WBC > 25,000 and Lactate > 2.2 are early warning signs of fulminant progression
Section 4
Next Steps
Therapeutic Escalation
01
Fulminant: Vanco (500mg QID po/NHT) + Metronidazole (500mg IV q8h). Include rectal vanco if ileus present.
02
Failure of Response: Consider fecal microbiota transplant (FMT) even in an acute severe setting if refractory.
Complementary Tools
ATLAS Score (CDI Prognosis)
Zar Score (CDI Predictor)
Section 5
Evidence Appraisal
2021 Guidelines
IDSA-SHEA 2021 Focused Update on Management of CDI in Adults.
Johnson S et al. • Clin Infect Dis.. 2021;73(7):e1029-e1044.
The Infectious Diseases Society of America (IDSA) panel developed these thresholds to harmonize antibiotic stewardship with physiological biomarkers of sepsis.
